Pricing Log in Create free account

Design Therapeutics, Inc. (DSGN) vs Kura Oncology, Inc. (KURA)

Design Therapeutics, Inc. and Kura Oncology, Inc. are both Biotechnology companies. Design Therapeutics, Inc. and Kura Oncology, Inc. are of similar size ($605.2M and $604.9M). Design Therapeutics, Inc. has the higher net margin (0.00% vs −384.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Design Therapeutics, Inc. leads on 11 and Kura Oncology, Inc. on 4.

Valuation

Metric DSGN KURA Biotechnology median
P/E n/m n/m 10.60
P/S 2,842.20 8.31 9.40
P/B 3.18 13.25 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 1,919.15 1.71 9.02
Earnings yield (11.79%) (46.68%) (32.88%)
Free cash flow yield (9.24%) (18.30%) (23.13%)

Profitability

Metric DSGN KURA Biotechnology median
Gross margin 0.00% 99.35% 68.51%
Operating margin 0.00% (411.90%) 0.00%
Net margin 0.00% (384.30%) 0.00%
Free cash flow margin 0.00% (152.06%) 0.00%
Return on equity (36.87%) (167.71%) (51.96%)
Return on assets (34.57%) (46.73%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric DSGN KURA Biotechnology median
Revenue growth (TTM) — — 6.76%
EPS growth (last fiscal year) (38.64%) (57.43%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DSGN KURA Biotechnology median
Debt to equity 0.00 0.20 0.00
Current ratio 16.78 4.73 4.97
Net debt to EBITDA 2.68 2.11 1.01

Dividend

Metric DSGN KURA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric DSGN KURA Biotechnology median
Market cap 605.16m 604.93m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack